Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Joseph Haas

Joseph Haas is a senior writer for Informa’s pharmaceutical news publications, with more than eight years covering the biopharmaceutical industry. He previously worked in public affairs for a real estate trade association and wrote about housing and real estate before moving into healthcare. Most recently, he was managing editor of a newsletter publisher, leading its coverage of the implementation of the Medicare Part D prescription drug benefit. Joe’s areas of expertise include business development, mergers and acquisitions, infectious diseases and liver diseases, including hepatitis C, hepatitis B and non-alcoholic steatohepatitis (NASH). He edits the popular Deal Watch column and enjoys profiling start-up companies. 
Advertisement
Set Alert for Articles By Joseph Haas

Latest From Joseph Haas

Snapshot Of The Opioid Crisis, An Infographic

The opioid market is expected to total $18.4bn by 2020 – but the growing crisis of opioid abuse plagues manufacturers, policy makers and public health. Scrip takes a look at the pipeline of abuse-deterrent formulations and physician opinions about what impact those will have.

Neurology Drug Safety

Allergan’s Two-Year NASH Data Fail To Show Fibrosis Benefit

A year after acquiring cenicriviroc in its Tobira buyout, Allergan says two-year data from a Phase IIb trial supports continued development, but analysts think the drug’s prospects have dimmed.

Clinical Trials Liver & Hepatic

Provention Builds On J&J Disease Interception Model

Founded earlier in 2017 with a plan of making quick "go/no-go" development decisions based on objective data, Provention taps into Johnson & Johnson for a pair of IBD candidates.

Deals Business Strategies

Parvus Seeks Autoimmune Answers Through Restoring Immune Tolerance

Emerging Company Profile: Partnered with Novartis on a nanoparticle candidate for type 1 diabetes, Parvus develops its proprietary Navacims to help the body’s immune system differ between a pathogen and itself.

StartUps and SMEs Business Strategies

APOLLO Success Clears Alnylam For Lift-Off

Phase III APOLLO results finally give the beleagured firm the first late-stage success for an RNAi thereapeutic and potentially a strong lead in the rare hereditary disease. 

Clinical Trials Drug Safety

Nuvelution Puts Business Model Into Action With Teva/Austedo Deal

Focused on drug development risk-sharing partnerships, Nuvelution signs its first partnership, with Teva, to conduct Phase III development of recently approved Austedo for pediatric Tourette syndrome.

Deals Research and Development Strategies
See All
Advertisement
UsernamePublicRestriction

Register